MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596742 | Name: Alatrofloxacin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Alatrofloxacin is a prodrug of trovafloxacin.

Chemical Structure

Alatrofloxacin
Alatrofloxacin
CAS#146961-76-4 (free base)

Theoretical Analysis

MedKoo Cat#: 596742

Name: Alatrofloxacin

CAS#: 146961-76-4 (free base)

Chemical Formula: C26H25F3N6O5

Exact Mass: 558.1839

Molecular Weight: 558.51

Elemental Analysis: C, 55.91; H, 4.51; F, 10.20; N, 15.05; O, 14.32

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
146961-77-5 (mesylate) 146961-76-4 (free base) 157605-25-9 (mesylate)
Synonym
Alatrofloxacin; CP 116,517; CP 116517; CP-116,517; CP-116517;
IUPAC/Chemical Name
7-((1R,5S,6s)-6-((S)-2-((S)-2-aminopropanamido)propanamido)-3-azabicyclo[3.1.0]hexan-3-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
InChi Key
UUZPPAMZDFLUHD-VUJLHGSVSA-N
InChi Code
InChI=1S/C26H25F3N6O5/c1-10(30)24(37)31-11(2)25(38)32-20-14-7-34(8-15(14)20)23-18(29)6-13-21(36)16(26(39)40)9-35(22(13)33-23)19-4-3-12(27)5-17(19)28/h3-6,9-11,14-15,20H,7-8,30H2,1-2H3,(H,31,37)(H,32,38)(H,39,40)/t10-,11-,14-,15+,20+/m0/s1
SMILES Code
C[C@H](N)C(N[C@H](C(N[C@H]1[C@H]2[C@@H]1CN(c(c(F)c3)nc4c3c(=O)c(C(O)=O)cn4c5c(F)cc(F)cc5)C2)=O)C)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 558.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Mukherjee J. Post-approval translational research itself has diverse ethics. Am J Bioeth. 2010 Aug;10(8):43-4. doi: 10.1080/15265161.2010.496525. PubMed PMID: 20694908. 2: Hsiao CJ, Younis H, Boelsterli UA. Trovafloxacin, a fluoroquinolone antibiotic with hepatotoxic potential, causes mitochondrial peroxynitrite stress in a mouse model of underlying mitochondrial dysfunction. Chem Biol Interact. 2010 Oct 6;188(1):204-13. doi: 10.1016/j.cbi.2010.07.017. Epub 2010 Jul 23. PubMed PMID: 20655887. 3: Annas GJ. Globalized clinical trials and informed consent. N Engl J Med. 2009 May 14;360(20):2050-3. doi: 10.1056/NEJMp0901474. PubMed PMID: 19439740. 4: Ezeome ER, Simon C. Ethical problems in conducting research in acute epidemics: the Pfizer meningitis study in Nigeria as an illustration. Dev World Bioeth. 2010 Apr;10(1):1-10. doi: 10.1111/j.1471-8847.2008.00239.x. Epub 2008 Jul 28. PubMed PMID: 18665846. 5: Jegede AS. Understanding informed consent for participation in international health research. Dev World Bioeth. 2009 Aug;9(2):81-7. doi: 10.1111/j.1471-8847.2008.00238.x. Epub 2008 Jul 15. PubMed PMID: 18637943. 6: Loewenberg S. Drug company trials come under increasing scrutiny. Lancet. 2008 Jan 19;371(9608):191-2. PubMed PMID: 18217230. 7: Aagaard L, Soendergaard B, Stenver DI, Hansen EH. Knowledge creation about ADRs--turning the perspective from the rear mirror to the projector? Br J Clin Pharmacol. 2008 Mar;65(3):364-76. Epub 2007 Oct 24. PubMed PMID: 17961195; PubMed Central PMCID: PMC2291241. 8: Willyard C. Pfizer lawsuit spotlights ethics of developing world clinical trials. Nat Med. 2007 Jul;13(7):763. Epub 2007 Jun 29. PubMed PMID: 17618250. 9: Lenzer J. Secret report surfaces showing that Pfizer was at fault in Nigerian drug tests. BMJ. 2006 May 27;332(7552):1233. PubMed PMID: 16735322; PubMed Central PMCID: PMC1471980. 10: Starr JA, Ragucci KR. Thrombocytopenia associated with intravenous ciprofloxacin. Pharmacotherapy. 2005 Jul;25(7):1030-4. PubMed PMID: 16006282. 11: Hall IH, Schwab UE, Ward ES, Ives TJ. Effects of alatrofloxacin, the parental prodrug of trovafloxacin, on phagocytic, anti-inflammatory and immunomodulation events of human THP-1 monocytes. Biomed Pharmacother. 2003 Oct;57(8):359-65. PubMed PMID: 14568230. 12: Lode H, Grossman C, Choudhri S, Haverstock D, McGivern J, Herman-Gnjidic Z, Church D. Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia. Respir Med. 2003 Oct;97(10):1134-42. PubMed PMID: 14561021. 13: Raufu A. Nigerians in drug trial take their case to US court. BMJ. 2003 Apr 26;326(7395):899. PubMed PMID: 12714459; PubMed Central PMCID: PMC1125820. 14: Nakamura T, Fukuda H, Morita Y, Soumi K, Kawamura Y. Pharmacological evaluation of garenoxacin, a novel des-F(6)-quinolone antimicrobial agent: effects on the central nervous system. J Toxicol Sci. 2003 Feb;28(1):35-45. PubMed PMID: 12696183. 15: Fry DE, Schermer CR. The consequences of suppression of anaerobic bacteria. Surg Infect (Larchmt). 2000;1(1):49-56. Review. PubMed PMID: 12594909. 16: Vaudaux P, Francois P, Bisognano C, Schrenzel J, Lew DP. Comparison of levofloxacin, alatrofloxacin, and vancomycin for prophylaxis and treatment of experimental foreign-body-associated infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2002 May;46(5):1503-9. PubMed PMID: 11959588; PubMed Central PMCID: PMC127155. 17: Brook I, Elliott TB, Pryor HI 2nd, Sautter TE, Gnade BT, Thakar JH, Knudson GB. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents. 2001 Dec;18(6):559-62. PubMed PMID: 11738344. 18: Ready T. Pfizer in "unethical" trial suit. Nat Med. 2001 Oct;7(10):1077. PubMed PMID: 11590414. 19: Pai MP, Bordley J 4th, Amsden GW. Plasma Pharmacokinetics and Tissue Penetration of Alatrofloxacin in Morbidly Obese Individuals. Clin Drug Investig. 2001 Mar;21(3):219-24. doi: 10.2165/00044011-200121030-00008. PubMed PMID: 27517552. 20: Mitropoulos FA, Angood PB, Rabinovici R. Trovafloxacin-associated leukopenia. Ann Pharmacother. 2001 Jan;35(1):41-4. PubMed PMID: 11197584.